Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.
CNBC's Meg Tirrell discusses the timeline on the war on drug pricing.
CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.
Debating whether California voters should pass Proposition 61, the Drug Price Relief Act, with Scott Gottlieb, physician and American Enterprise Institute Resident Fellow, and Zeke Emanuel, University of Pennsylvania vice provost for global initiatives.
Jim Cramer addressed the stunning decline in McKesson, and got to the bottom of what triggered the sudden fall in the stock.
CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.
CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.
Walgreens Boots Alliance reported a jump in quarterly profit and said it now expected its acquisition of Rite Aid Corp to close in early 2017.
Democratic vice presidential candidate Tim Kaine discusses Donald Trump's tax plan and Hillary Clinton's Catholic comments in the Wikileaks emails.
Democratic vice presidential candidate Tim Kaine discusses lowering drug prices, Wall Street and regulation and estate taxes.
CNBC's Meg Tirrell reports the latest on the controversy surrounding the California Drug Price Relief Act including the Bernie Sanders' support for the proposition.
Dr. Peter Bach, Memorial Sloan Kettering physician, discusses how copay assistance programs are actually causing drug prices to rise.
CNBC's Meg Tirrell discusses implications surrounding co-pay assistance programs.
CNBC's Bertha Coombs reports the latest troubles in health care, including why shares of Humana are sinking.
Jim Cramer says uncertainty surrounding a Democratic win for the White House puts drug stocks in the danger zone.
David Maris, Wells Fargo Securities, discusses where he foresees trouble in the biotech sector, as well finding safety in these cases.
CNBC's Meg Tirrell reports the latest trouble in the biotech sector, specifically involving Illumina and Theranos.
CNBC's Meg Tirrell reports on the moves in cancer drugmakers following the European Cancer Congress in Copenhagen. The "FMHR" traders weigh in.
CNBC's Meg Tirrell reports the latest of the EpiPen controversy, including confirmation of Mylan overcharging Medicaid. CNBC senior markets contributor Mike Santoli and "Fast Money" trader Steve Grasso weigh in.